全文获取类型
收费全文 | 105894篇 |
免费 | 8875篇 |
国内免费 | 2487篇 |
专业分类
耳鼻咽喉 | 445篇 |
儿科学 | 3809篇 |
妇产科学 | 1128篇 |
基础医学 | 9099篇 |
口腔科学 | 1478篇 |
临床医学 | 13143篇 |
内科学 | 28912篇 |
皮肤病学 | 1149篇 |
神经病学 | 3181篇 |
特种医学 | 1746篇 |
外国民族医学 | 6篇 |
外科学 | 10286篇 |
综合类 | 17357篇 |
现状与发展 | 7篇 |
一般理论 | 1篇 |
预防医学 | 6342篇 |
眼科学 | 656篇 |
药学 | 10356篇 |
79篇 | |
中国医学 | 6080篇 |
肿瘤学 | 1996篇 |
出版年
2024年 | 100篇 |
2023年 | 1910篇 |
2022年 | 2486篇 |
2021年 | 4469篇 |
2020年 | 4500篇 |
2019年 | 3929篇 |
2018年 | 3790篇 |
2017年 | 3829篇 |
2016年 | 4106篇 |
2015年 | 3984篇 |
2014年 | 7879篇 |
2013年 | 8243篇 |
2012年 | 7121篇 |
2011年 | 7682篇 |
2010年 | 5965篇 |
2009年 | 5785篇 |
2008年 | 5481篇 |
2007年 | 5113篇 |
2006年 | 4462篇 |
2005年 | 4096篇 |
2004年 | 3176篇 |
2003年 | 2618篇 |
2002年 | 2177篇 |
2001年 | 2011篇 |
2000年 | 1514篇 |
1999年 | 1296篇 |
1998年 | 1041篇 |
1997年 | 927篇 |
1996年 | 863篇 |
1995年 | 793篇 |
1994年 | 785篇 |
1993年 | 601篇 |
1992年 | 566篇 |
1991年 | 499篇 |
1990年 | 441篇 |
1989年 | 421篇 |
1988年 | 383篇 |
1987年 | 321篇 |
1986年 | 278篇 |
1985年 | 286篇 |
1984年 | 232篇 |
1983年 | 142篇 |
1982年 | 173篇 |
1981年 | 141篇 |
1980年 | 118篇 |
1979年 | 112篇 |
1978年 | 89篇 |
1977年 | 85篇 |
1976年 | 75篇 |
1974年 | 37篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
12.
13.
《Saudi Pharmaceutical Journal》2022,30(5):595-604
Anthrax is a zoonotic infection caused by the gram-positive, aerobic, spore-forming bacterium Bacillus anthracis. Depending on the origin of the infection, serious health problems or mortality is possible. The virulence of B. anthracis is reliant on three pathogenic factors, which are secreted upon infection: protective antigen (PA), lethal factor (LF), and edema factor (EF). Systemic illness results from LF and EF entering cells through the formation of a complex with the heptameric form of PA, bound to the membrane of infected cells through its receptor. The currently available anthrax vaccines have multiple drawbacks, and recombinant PA is considered a promising second-generation vaccine candidate. However, the inherent chemical instability of PA through Asn deamidation at multiple sites prevents its use after long-term storage owing to loss of potency. Moreover, there is a distinct possibility of B. anthracis being used as a bioweapon; thus, the developed vaccine should remain efficacious and stable over the long-term. Second-generation anthrax vaccines with appropriate adjuvant formulations for enhanced immunogenicity and safety are desired. In this article, using protein engineering approaches, we have reviewed the stabilization of anthrax vaccine candidates that are currently licensed or under preclinical and clinical trials. We have also proposed a formulation to enhance recombinant PA vaccine potency via adjuvant formulation. 相似文献
14.
15.
16.
《Value in health》2022,25(7):1235-1252
ObjectivesThe incidence of type 1 diabetes mellitus is increasing every year requiring substantial expenditure on treatment and complications. A systematic review was conducted on the cost-effectiveness of insulin formulations, including ultralong-, long-, or intermediate-acting insulin, and their biosimilar insulin equivalents.MethodsMEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, HTA, and NHS EED were searched from inception to June 11, 2021. Cost-effectiveness and cost-utility analyses were included if insulin formulations in adults (≥ 16 years) with type 1 diabetes mellitus were evaluated. Two reviewers independently screened titles, abstracts, and full-text articles, extracted study data, and appraised their quality using the Drummond 10-item checklist. Costs were converted to 2020 US dollars adjusting for inflation and purchasing power parity across currencies.ResultsA total of 27 studies were included. Incremental cost-effectiveness ratios ranged widely across the studies. All pairwise comparisons (11 of 11, 100%) found that ultralong-acting insulin was cost-effective compared with other long-acting insulins, including a long-acting biosimilar. Most pairwise comparisons (24 of 27, 89%) concluded that long-acting insulin was cost-effective compared with intermediate-acting insulin. Few studies compared long-acting insulins with one another.ConclusionsLong-acting insulin may be cost-effective compared with intermediate-acting insulin. Future studies should directly compare biosimilar options and long-acting insulin options and evaluate the long-term consequences of ultralong-acting insulins. 相似文献
17.
18.
19.
20.